Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Clinical role
Adjunctive risk-estimation support after the labeled screening interpretation workflow.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: The output is not a diagnosis, cancer-detection result, care recommendation, or sole determinant of care; exact acquisition and eligibility criteria apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Supported bilateral screening mammograms and the patient eligibility data described in the exact De Novo submission.
Who uses it?Intended users: Radiologists, breast-imaging professionals, and other trained healthcare professionals authorized by the labeled workflow.
What does the software produce?Output: A labeled five-year risk percentage for professional review and clinical-context discussion.
What is its most important limitation?Key limitation: The output is not a diagnosis, cancer-detection result, care recommendation, or sole determinant of care; exact acquisition and eligibility criteria apply.
Clinical takeaway. Clinical role: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a multi-site retrospective pivotal study of 77,511 exams from 44,112 patients at five validation sites independent of training data, with biopsy-proven breast cancer within five years as ground truth. In the total study population, AUC(5) was 0.70 [0.69, 0.72] (95% confidence interval), above the 0.64 performance goal, and calibration was met (modified GND p-value < 0.001); excluding current cancers, AUC(5) was 0.66 [0.66, 0.68]. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
The output is not a diagnosis, cancer-detection result, care recommendation, or sole determinant of care; exact acquisition and eligibility criteria apply.
The exact FDA document reports a multi-site retrospective pivotal study of 77,511 exams from 44,112 patients at five validation sites independent of training data, with biopsy-proven breast cancer within five years as ground truth. In the total study population, AUC(5) was 0.70 [0.69, 0.72] (95% confidence interval), above the 0.64 performance goal, and calibration was met (modified GND p-value < 0.001); excluding current cancers, AUC(5) was 0.66 [0.66, 0.68]. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "A multi-site retrospective powered study was conducted as a premarket pivotal study to demonstrate the predictive capability of the Allix5 device. Clinical Sites and Patient Demographics A total of 77,511 exams were collected from 44,112 patients in the following five validation sites" … "Use of these five clinical validation sites provided data that is independent of the data and sites used for algorithm training and tuning.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a multi-site retrospective pivotal study of 77,511 exams from 44,112 patients at five validation sites independent of training data, with biopsy-proven breast cancer within five years as ground truth. In the total study population, AUC(5) was 0.70 [0.69, 0.72] (95% confidence interval), above the 0.64 performance goal, and calibration was met (modified GND p-value < 0.001); excluding current cancers, AUC(5) was 0.66 [0.66, 0.68]. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "A multi-site retrospective powered study was conducted as a premarket pivotal study to demonstrate the predictive capability of the Allix5 device. Clinical Sites and Patient Demographics A total of 77,511 exams were collected from 44,112 patients in the following five validation sites" … "Use of these five clinical validation sites provided data that is independent of the data and sites used for algorithm training and tuning.". Read from the exact FDA decision document on 2026-11-14.
No exact submission-linked sensitivity endpoint with a verified population, threshold, tested version, and source was promoted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission-linked specificity endpoint with a verified population, threshold, tested version, and source was promoted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DEN240047 FDA evidence package for Allix5
DesignFDA De Novo decision evidence package reviewed for exact submission identity and labeled scope
PopulationLabeled population and configuration described in the DEN240047 FDA decision material
Scopeexact submission
Tested versionAllix5 configuration described in DEN240047
IndependenceSponsor or vendor study
DEN240047
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to DEN240047 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported bilateral screening mammograms and the patient eligibility data described in the exact De Novo submission.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Allix5 as integrated into existing clinical information systems without an independent user interface, receiving DICOM files from a PACS and automatically returning its output via HL7. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "The Allix5 device is designed to be integrated into existing clinical information systems that are already part of healthcare provider workflows; it does not have an independent user interface." … "The Allix5 device receives DICOM files from a PACS and automatically returns the Allix5 output via HL7.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: A labeled five-year risk percentage for professional review and clinical-context discussion.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A labeled five-year risk percentage for professional review and clinical-context discussion.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Allix5 as integrated into existing clinical information systems without an independent user interface, receiving DICOM files from a PACS and automatically returning its output via HL7. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The Allix5 device is designed to be integrated into existing clinical information systems that are already part of healthcare provider workflows; it does not have an independent user interface." … "The Allix5 device receives DICOM files from a PACS and automatically returns the Allix5 output via HL7.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Only radiologists, breast-imaging professionals, and other trained healthcare professionals authorized by the labeled workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, report, and downtime contract locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the exact labeled population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The output is not a diagnosis, cancer-detection result, care recommendation, or sole determinant of care; exact acquisition and eligibility criteria apply.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. No exact native-submission recall record was found in the checked snapshot; this does not exclude other product-family or later signals.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Installation timeline: Not yet reviewed
Monitoring: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision and checked recall snapshot do not establish a complete local postmarket monitoring protocol. Track version, population, anatomy, protocol, input quality, edits, failures, repeats, downstream effects, downtime, incidents, recalls, and updates locally.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.